These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 29754832)

  • 1. Ondansetron in Pregnancy and the Risk of Congenital Malformations: A Systematic Review.
    Lavecchia M; Chari R; Campbell S; Ross S
    J Obstet Gynaecol Can; 2018 Jul; 40(7):910-918. PubMed ID: 29754832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ondansetron Use During Pregnancy: Birth Defects and Obstetric Outcomes.
    Masarwe S; Shvartsur R; Hadar E; Betesh-Abay B; Peleg N; Azab AN
    Clin Nurs Res; 2023 May; 32(4):705-711. PubMed ID: 36912091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ondansetron should never be used in pregnancy: Against: Ondansetron in pregnancy revisited.
    Damkier P; Kaplan YC; Shechtman S; Diav-Citrin O; Cassina M; Weber-Schoendorfer C; Cleary B; Hodson K
    BJOG; 2021 Jan; 128(1):111-112. PubMed ID: 32991063
    [No Abstract]   [Full Text] [Related]  

  • 4. Ondansetron should never be used in pregnancy.
    Kirby RS
    BJOG; 2021 Jan; 128(1):113. PubMed ID: 32974914
    [No Abstract]   [Full Text] [Related]  

  • 5. Association of Maternal First-Trimester Ondansetron Use With Cardiac Malformations and Oral Clefts in Offspring.
    Huybrechts KF; Hernández-Díaz S; Straub L; Gray KJ; Zhu Y; Patorno E; Desai RJ; Mogun H; Bateman BT
    JAMA; 2018 Dec; 320(23):2429-2437. PubMed ID: 30561479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ondansetron Use in Pregnancy and Birth Defects: A Systematic Review.
    Carstairs SD
    Obstet Gynecol; 2016 May; 127(5):878-883. PubMed ID: 27054939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ondansetron in pregnancy and risk of adverse fetal outcomes in the United States.
    Fejzo MS; MacGibbon KW; Mullin PM
    Reprod Toxicol; 2016 Jul; 62():87-91. PubMed ID: 27151373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interventions for treating hyperemesis gravidarum: a Cochrane systematic review and meta-analysis.
    Boelig RC; Barton SJ; Saccone G; Kelly AJ; Edwards SJ; Berghella V
    J Matern Fetal Neonatal Med; 2018 Sep; 31(18):2492-2505. PubMed ID: 28614956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Pregnancy Outcomes of Patients Treated With Ondansetron vs Alternative Antiemetic Medications in a Multinational, Population-Based Cohort.
    Dormuth CR; Winquist B; Fisher A; Wu F; Reynier P; Suissa S; Dahl M; Ma Z; Lu X; Zhang J; Raymond CB; Filion KB; Platt RW; Moriello C; Paterson JM;
    JAMA Netw Open; 2021 Apr; 4(4):e215329. PubMed ID: 33890993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ondansetron Use in Pregnancy.
    Siminerio LL; Bodnar LM; Venkataramanan R; Caritis SN
    Obstet Gynecol; 2016 May; 127(5):873-877. PubMed ID: 27054931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Off-label use of ondansetron in pregnancy in Western Australia.
    Colvin L; Gill AW; Slack-Smith L; Stanley FJ; Bower C
    Biomed Res Int; 2013; 2013():909860. PubMed ID: 24396830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of gabapentin on hyperemesis gravidarum: a double-blind, randomized controlled trial.
    Guttuso T; Messing S; Tu X; Mullin P; Shepherd R; Strittmatter C; Saha S; Thornburg LL
    Am J Obstet Gynecol MFM; 2021 Jan; 3(1):100273. PubMed ID: 33451591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of ondansetron during pregnancy and the risk of major congenital malformations: A systematic review and meta-analysis.
    Kaplan YC; Richardson JL; Keskin-Arslan E; Erol-Coskun H; Kennedy D
    Reprod Toxicol; 2019 Jun; 86():1-13. PubMed ID: 30849498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First trimester ondansetron exposure and risk of structural birth defects.
    Zambelli-Weiner A; Via C; Yuen M; Weiner DJ; Kirby RS
    Reprod Toxicol; 2019 Jan; 83():14-20. PubMed ID: 30385129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validating the effect of Ondansetron and Mirtazapine In Treating hyperemesis gravidarum (VOMIT): protocol for a randomised placebo-controlled trial.
    Ostenfeld A; Petersen TS; Futtrup TB; Andersen JT; Jensen AK; Westergaard HB; Pedersen LH; Løkkegaard ECL
    BMJ Open; 2020 Mar; 10(3):e034712. PubMed ID: 32209630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The safety of ondansetron for nausea and vomiting of pregnancy: a prospective comparative study.
    Einarson A; Maltepe C; Navioz Y; Kennedy D; Tan MP; Koren G
    BJOG; 2004 Sep; 111(9):940-3. PubMed ID: 15327608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pilot study of intravenous ondansetron for hyperemesis gravidarum.
    Sullivan CA; Johnson CA; Roach H; Martin RW; Stewart DK; Morrison JC
    Am J Obstet Gynecol; 1996 May; 174(5):1565-8. PubMed ID: 9065130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of malformation after ondansetron in pregnancy: An updated systematic review and meta-analysis.
    Picot C; Berard A; Grenet G; Ripoche E; Cucherat M; Cottin J
    Birth Defects Res; 2020 Aug; 112(13):996-1013. PubMed ID: 32420702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of ondansetron during pregnancy and congenital malformations in the infant.
    Danielsson B; Wikner BN; Källén B
    Reprod Toxicol; 2014 Dec; 50():134-7. PubMed ID: 25450422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ondansetron for Treatment of Nausea and Vomiting of Pregnancy and the Risk of Specific Birth Defects.
    Parker SE; Van Bennekom C; Anderka M; Mitchell AA;
    Obstet Gynecol; 2018 Aug; 132(2):385-394. PubMed ID: 29995744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.